Johns Hopkins ABX Guide
Sofosbuvir
INDICATIONS
FDA
FDA
- Treatment of HCV genotype 1, 2, 3, or 4 as a component of a combination antiviral treatment regimen
- Indicated in patients with hepatocellular carcinoma, those awaiting liver transplantation, and those with HCV/HIV-1 co-infection
- Pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without cirrhosis or with compensated cirrhosis in combination with ribavirin
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- In combination with an HCV active antiviral regimen, sofosbuvir’s (SOF) efficacy has been established in patients with HCV genotypes 5 and 6
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: August 3, 2023
Citation
Auwaerter, Paul G, and Janessa M Smith. "Sofosbuvir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540635/all/Sofosbuvir.
Auwaerter PG, Smith JM. Sofosbuvir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540635/all/Sofosbuvir. Accessed May 10, 2025.
Auwaerter, P. G., & Smith, J. M. (2023). Sofosbuvir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540635/all/Sofosbuvir
Auwaerter PG, Smith JM. Sofosbuvir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2025 May 10]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540635/all/Sofosbuvir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Sofosbuvir
ID - 540635
A1 - Auwaerter,Paul,M.D.
AU - Smith,Janessa,Pharm.D. BCPS
Y1 - 2023/08/03/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540635/all/Sofosbuvir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
